Technical Analysis for RDHL - Redhill Biopharma Ltd.

Grade Last Price % Change Price Change
grade A 8.75 9.51% 0.76
RDHL closed up 9.51 percent on Friday, August 7, 2020, on 2.5 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical RDHL trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Upper Bollinger Band Walk Strength 9.51%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.
Medicine Biopharmaceutical Autoimmune Diseases Inflammatory Bowel Disease Antibiotics Heart Failure Hypertension Gastroenterology Abdominal Pain Bacteria Crohn's Disease Nausea Treatment Of Inflammatory Bowel Disease Vomiting Treatment Of Hypertension Ventricular Dysfunction

Is RDHL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.12
52 Week Low 3.2621
Average Volume 327,542
200-Day Moving Average 6.20
50-Day Moving Average 7.02
20-Day Moving Average 7.12
10-Day Moving Average 7.53
Average True Range 0.54
ADX 22.39
+DI 39.74
-DI 11.68
Chandelier Exit (Long, 3 ATRs ) 7.47
Chandelier Exit (Short, 3 ATRs ) 7.68
Upper Bollinger Band 8.35
Lower Bollinger Band 5.89
Percent B (%b) 1.16
BandWidth 34.54
MACD Line 0.32
MACD Signal Line 0.16
MACD Histogram 0.1632
Fundamentals Value
Market Cap 150.17 Million
Num Shares 17.2 Million
EPS -2.46
Price-to-Earnings (P/E) Ratio -3.56
Price-to-Sales 264.36
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.57
Resistance 3 (R3) 10.48 9.78 10.26
Resistance 2 (R2) 9.78 9.32 9.83 10.16
Resistance 1 (R1) 9.27 9.04 9.53 9.36 10.06
Pivot Point 8.57 8.57 8.70 8.62 8.57
Support 1 (S1) 8.06 8.11 8.32 8.15 7.44
Support 2 (S2) 7.36 7.83 7.41 7.34
Support 3 (S3) 6.85 7.36 7.24
Support 4 (S4) 6.94